TABLE OF CONTENTS

In This Issue/Research Watch/News in Brief..............................................1323

From the IASLC Tobacco Control Committee..............................................1327

EDITORIALS

Immune Checkpoint Inhibition for Locally Advanced NSCLC:
Time to Ask New Questions?.................................................................1330
Jeffrey A. Bogart, MD

Pericardial Mesothelioma, a Disease for Brave Hearts.........................1333
Federica Grosso, MD, Luigi Cerbone, MD, and Giulia Pasello, MD, PhD

About the Cover: the cover image is from Figure 1 in the article by He on page 1375.

E denotes online only article

OPEN ACCESS denotes Open Access article

(continued on next page)
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee

Mari Mino-Kenudson, MD, Kurt Schalper, MD, PhD, Wendy Cooper, M.B.B.S., PhD, Sanja Dacic, MD, PhD, Fred R. Hirsch, MD, PhD, Deepali Jain, MD, Fernando Lopez-Rios, MD, PhD, Ming Sound Tsao, MD, Yasushi Yatabe, MD, PhD, Mary Beth Beasley, MD, Hui Yu, MD, Lynette M. Sholl, MD, Elizabeth Brambilla, MD, PhD, Teh-Ying Chou, MD, PhD, Casey Connolly, MPH, Ignacio Wistuba, MD, PhD, Keith M. Kerr, MD, and Sylvie Lantuejoul, MD, PhD, IASLC Pathology Committee

Screening

Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose Computed Tomography Screening

Anil Vachani, MD, MS, Nikki M. Carroll, MS, Michael J. Simoff, MD, Christine Neslund-Dudas, PhD, Stacey Honda, MD, PhD, Robert T. Greenlee, PhD, MPH, Katharine A. Rendle, PhD, MSW, MPH, Andrea Burnett-Hartman, PhD, and Debra P. Ritzwoller, PhD

Translational Oncology

Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit

Emily Pei-Ying Lin, MD, PhD, Chih-Yuan Hsu, PhD, Jeng-Fong Chiou, MD, PhD, Lynne Berry, PhD, Leora Horn, MD, MSc, Paul Bunn, MD, James Chih-Hsin Yang, MD, PhD, Pan-Chyr Yang, MD, PhD, Alex A. Adjei, MD, PhD, and Yu Shyr, PhD

A Knock-In Mouse Model of Thymoma With the GTF2I L424H Mutation

Yongfeng He, PhD, In-Kyu Kim, PhD, Jing Bian, BS, Alexander Polyzos, PhD, Dafne Campigli Di Giammartino, PhD, Yu-Wen Zhang, MD, PhD, Ji Luo, PhD, Maria O. Hernandez, PhD, Noemi Kedei, MD, Maggie Cam, PhD, Alain C. Borczuk, MD, Trevor Lee, BS, Yumin Han, PhD, Elizabeth A. Conner, PhD, Madeline Wong, PhD, Desiree C. Tillo, PhD, Shigeki Umemura, MD, PhD, Vincent Chen, PhD, Lydia Ruan, HS, Jessica B. White, MS, Icana C. Miranda, MSc, Parirokh P. Awasthi, MSc, Nasser K. Altorki, MD, Prajan Divakar, PhD, Olivier Elemento, PhD, Effie Apostolou, PhD, and Giuseppe Giaccone, MD, PhD

YES1 Is a Druggable Oncogenic Target in SCLC

Esther Redin, PhD, Eva M. Garrido-Martin, PhD, Karmele Valencia, PhD, Miriam Redrado, BS, Jose Luis Solorzano, MD, Rafael Carias, MD, Mirari Echepare, MS, Francisco Exposito, PhD, Diego Serrano, PhD, Irene Ferrer, PhD, Angel Nunez-Buiza, MS, Irati Garmendia, PhD, Juana M. García-Pedrero, PhD, Alfonso Gurpide, MD, Luis Paz-Ares, MD, PhD, Katerina Politi, PhD, Luis M. Montuenga, PhD, and Alfonso Calvo, PhD

(continued on next page)
TABLE OF CONTENTS (continued)

Non-Small Cell Lung Cancer

**OPEN ACCESS** Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) ........................................................... 1404
Sai-Hong Ignatius Ou, MD, PhD, Makoto Nishio, MD, PhD, Myung-Ju Ahn, MD, PhD, Tony Mok, MD, Fabrice Barlesi, MD, PhD, Caicun Zhou, MD, PhD, Enriqueta Felip, MD, PhD, Filippo de Marinis, MD, Sang-We Kim, MD, PhD, Maurice Pérol, MD, Geoffrey Liu, MD, MSc, Maria Rita Migliorino, MD, Dong-Wan Kim, MD, PhD, Silvia Novello, MD, PhD, Alessandra Bearz, MD, Pilar Garrido, MD, PhD, Julien Mazieres, MD, PhD, Alessandro Morabito, MD, Huamao M. Lin, PhD, Hui Yang, PhD, Huifeng Niu, PhD, Pingkuan Zhang, MD, and Edward S. Kim, MD

**OPEN ACCESS** Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial ............... 1415
Marina C. Garassino, MD, Julien Mazieres, MD, Martin Reck, MD, Christos Chouaid, MD, Helge Bischoff, MD, Niels Reinmuth, MD, Laura Cove-Smith, MBChB, Talal Mansy, MBBS, Diego Cortinovis, MD, Maria R. Migliorino, MD, Angelo Delmonte, MD, José García Sánchez, MD, Luis Enrique Chara Velarde, MD, Reyes Bernabe, MD, Luis Paz-Ares, MD, Ignacio Díaz Perez, MD, Nataliya Trunova, MD, Kayhan Foroutanpour, PhD, and Corinne Faivre-Finn, MD

BRIEF REPORT

Multimodality Therapy in Patients With Primary Pericardial Mesothelioma............................................................... 1428
Michael Offin, MD, Dilanka L. De Silva, FRACP, Jennifer L. Sauter, MD, Jacklynn V. Egger, BS, Ellen Yorke, PhD, Prasad S. Adusumilli, MD, FACS, Andreas Rimner, MD, Valerie W. Rusch, MD, FACS, and Marjorie G. Zauberer, MD

LETTERS TO THE EDITOR

**e** What About Palliative and Supportive Care Landscapes? ................. e95
Tadashi Nishimura, MD

**e** In Response: Letter Received From Dr. Tadashi Nishimura Titled “What About Palliative and Supportive Care Landscapes?” .................. e95
Dhruba Deb, MD, Amy C. Moore, PhD, and Upal Basu Roy, PhD, MPH

Photocopying: Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission is not required for photocopying of articles published under the CC BY license nor for photocopying for non-commercial purposes in accordance with any other user license applied by the publisher. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Derivative Works: Users may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions or companies. Other than for articles published under the CC BY license, permission of the publisher is required for resale or distribution outside the subscribing institution or company.

For any subscribed articles or articles published under a CC BY-NC-ND license, permission of the publisher is required for all other derivative works, including compilations and translations.

Storage or Usage: Except as outlined above or as set out in the relevant user license, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Permissions: For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843830 (UK) / (+1) 215 239 3804 (USA).

Author rights: Author(s) may have additional rights in their articles as set out in their agreement with the publisher (more information at http://www.elsevier.com/authorrights).